UTokyo's Innovation Platform joined subsidiaries of SBI, Sumitomo Mitsui and Mizuho Bank to help double genetic disorder treatment developer EdiGene's funding.
EdiGene, a Japan-based developer of genetic disorder treatments based on gene editing techniques, raised an initial ¥1.6bn ($15m) in series B funding yesterday from investors including University of Tokyo’s investment company UTokyo Innovation Platform.
The round featured SBI Investment, SMBC Capital and Mizuho Capital – respective investment subsidiaries of financial services firms SBI Group, Sumitomo Mitsui Banking Corporation and Mizuho Bank.
Business development consultancy Fast Track Initiative and CareNet Group also took part in the transaction, together with…
